Provided By Globe Newswire
Last update: Apr 8, 2022
LEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-12 in New Orleans, LA.
Read more at globenewswire.comNASDAQ:AGEN (7/15/2025, 10:08:07 AM)
6.5101
-0.32 (-4.68%)
Find more stocks in the Stock Screener